It was recently revealed that a Singapore originated clinical biotech start-up, AUM Biosciences, announced the successful completion of USD $27 million series A funding round. This round was led by private equity funds including Singapore-based Everlife and globally focused health sciences investment firm SPRIM Global investments (SGI). Vishal Doshi, CEO & Co-Founder, AUM Biosciences shares an overview of the world's current oncology market and how AUM plays a role in changing the landscape. 

<p>It was recently revealed that a Singapore originated clinical biotech start-up, AUM Biosciences, announced the successful completion of USD $27 million series A funding round. This round was led by private equity funds including Singapore-based Everlife and globally focused health sciences investment firm SPRIM Global investments (SGI). <strong>Vishal Doshi, CEO &amp; Co-Founder, AUM Biosciences </strong>shares an overview of the world's current oncology market and how AUM plays a role in changing the landscape.&nbsp;</p>

Advertisement